EBMT 2016 | Side-effects of inotuzumab ozogamicin
Giovanni Martinelli
• 4 Apr 2016
Giovanni Martinelli, MD, from the University of Bologna, Bologna, Italy discusses the side-effects of inotuzumab ozogamicin, which targets CD22 in adult acute lymphoblastic leukemia (ALL) patients. According to Prof Martinelli, due to the specificity of the drug, severe side-effects are not to be expected. This means that the drug can also be given to elderly patients with acute leukemia. The majority of patients, 82%, responded very well to the drug according to Prof Martinelli.
Recorded at the 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Valencia, Spain.
